Related Experiment Video
Updated: Jul 16, 2026
Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model
Published on: September 8, 2023
Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone
Anbo Xiang1, Masahiro Kanematsu, Sanjay Kumar
1Department of Pharmacology, Tsukuba Research Laboratories, GlaxoSmithKline K.K., 43 Wadai, Tsukuba, Ibaraki 300-4247, Japan.
Abstract:
Cathepsin K is a cysteine proteinase that is highly expressed by osteoclasts and is being pursued as a potential drug target for the treatment of osteoporosis. We have reported that microcomputed tomography (micro-CT) analysis of bone microarchitecture may serve as a valuable tool for evaluating both antiresorptive and anabolic agents in ovariectomized (OVX) mice. The purpose of this study was to evaluate the effect of SB-553484, a novel cathepsin K inhibitor (human Ki,app=0.14 nM, mouse Ki,app=26 nM), on the OVX mice by micro-CT bone morphometric analysis. Seven weeks female BALB/c mice were OVX or sham-operated. OVX animals were treated with SB-553484 (30 mg/kg, sc) or Rolipram (10 mg/kg, po), a phosphodiesterase 4 inhibitor used as a positive bone anabolic agent, twice a day for 2 weeks. Both SB-553484 and Rolipram significantly prevented the decrease of trabecular bone volume as well as the deterioration of trabecular architecture in OVX mice. Interestingly, SB-553484 demonstrated a more pronounced effect in improvement of trabecular separation, number and connectivity, and a weaker effect in improvement of trabecular thickness compared to that of Rolipram. These differences indicate that SB-553484 mainly acted as an antiresorptive agent in OVX-induced loss of trabecular bone. On the other hand, SB-553484 significantly increased cortical bone volume and cortical thickness as well as Rolipram in OVX mice indicating an unexpected stimulatory effect of SB-553484 on cortical bone formation. These data suggest that targeting cathepsin K may prove therapeutically beneficial in the treatment of diseases with accelerated bone loss such as postmenopausal osteoporosis not only by inhibiting bone resorption but also by potentially stimulating cortical bone formation.
Insights
SB-553484, a cathepsin K inhibitor, prevented bone loss in ovariectomized mice by inhibiting resorption and unexpectedly stimulating cortical bone formation. This suggests targeting cathepsin K for osteoporosis treatment.
Area of Science:
- Biochemistry
- Pharmacology
- Orthopedics
Background:
- Cathepsin K is a key enzyme in osteoclast function and a therapeutic target for osteoporosis.
- Microcomputed tomography (micro-CT) is a valuable tool for assessing bone microarchitecture changes.
- Ovariectomized (OVX) mice models are widely used to study osteoporosis and evaluate bone-acting agents.
Purpose of the Study:
- To evaluate the efficacy of SB-553484, a novel cathepsin K inhibitor, on bone microarchitecture in OVX mice.
- To compare the effects of SB-553484 with Rolipram, a known bone anabolic agent, using micro-CT analysis.
- To determine the mechanism of action of SB-553484 in preventing OVX-induced bone loss.
Main Methods:
- Female BALB/c mice underwent OVX or sham surgery.
- OVX mice were treated with SB-553484 (cathepsin K inhibitor) or Rolipram (PDE4 inhibitor) for two weeks.
- Bone morphometric analysis was performed using micro-CT to assess trabecular and cortical bone parameters.
Main Results:
- Both SB-553484 and Rolipram significantly preserved trabecular bone volume and architecture in OVX mice.
- SB-553484 showed a stronger effect on trabecular separation, number, and connectivity, indicating antiresorptive action.
- SB-553484 unexpectedly increased cortical bone volume and thickness, suggesting a stimulatory effect on cortical bone formation.
Conclusions:
- SB-553484 effectively mitigates OVX-induced bone loss, primarily through antiresorptive mechanisms.
- The cathepsin K inhibitor SB-553484 demonstrates a novel anabolic effect on cortical bone formation.
- Targeting cathepsin K offers a promising therapeutic strategy for osteoporosis, potentially combining anti-resorptive and bone-building effects.
